CN1194764C - 镭－223在制备用于治疗影响骨的疾病的药物中的用途 - Google Patents

镭－223在制备用于治疗影响骨的疾病的药物中的用途 Download PDF

Info

Publication number
CN1194764C
CN1194764C CNB998161020A CN99816102A CN1194764C CN 1194764 C CN1194764 C CN 1194764C CN B998161020 A CNB998161020 A CN B998161020A CN 99816102 A CN99816102 A CN 99816102A CN 1194764 C CN1194764 C CN 1194764C
Authority
CN
China
Prior art keywords
bone
radium
treatment
medicine
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB998161020A
Other languages
English (en)
Chinese (zh)
Other versions
CN1335779A (zh
Inventor
罗伊·H·拉森
杰芒德·亨里克森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Anticancer Therapeutic Inventions AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anticancer Therapeutic Inventions AS filed Critical Anticancer Therapeutic Inventions AS
Publication of CN1335779A publication Critical patent/CN1335779A/zh
Application granted granted Critical
Publication of CN1194764C publication Critical patent/CN1194764C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Materials For Medical Uses (AREA)
  • Compounds Of Unknown Constitution (AREA)
CNB998161020A 1999-01-04 1999-12-17 镭－223在制备用于治疗影响骨的疾病的药物中的用途 Expired - Lifetime CN1194764C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO990001A NO310544B1 (no) 1999-01-04 1999-01-04 Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO19990001 1999-01-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2004100749238A Division CN1767078B (zh) 1999-01-04 1999-12-17 制备镭-223的方法、生理学上可接受的制剂和试剂盒

Publications (2)

Publication Number Publication Date
CN1335779A CN1335779A (zh) 2002-02-13
CN1194764C true CN1194764C (zh) 2005-03-30

Family

ID=19902803

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB998161020A Expired - Lifetime CN1194764C (zh) 1999-01-04 1999-12-17 镭－223在制备用于治疗影响骨的疾病的药物中的用途
CN2004100749238A Expired - Lifetime CN1767078B (zh) 1999-01-04 1999-12-17 制备镭-223的方法、生理学上可接受的制剂和试剂盒

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2004100749238A Expired - Lifetime CN1767078B (zh) 1999-01-04 1999-12-17 制备镭-223的方法、生理学上可接受的制剂和试剂盒

Country Status (24)

Country Link
US (2) US6635234B1 (enExample)
EP (1) EP1140212B1 (enExample)
JP (2) JP4649044B2 (enExample)
KR (1) KR100671387B1 (enExample)
CN (2) CN1194764C (enExample)
AT (1) ATE331534T1 (enExample)
AU (1) AU774991B2 (enExample)
BE (1) BE2014C028I2 (enExample)
BR (1) BR9916768A (enExample)
CA (1) CA2358498C (enExample)
CY (2) CY1105634T1 (enExample)
DE (1) DE69932183T2 (enExample)
DK (1) DK1140212T3 (enExample)
EA (1) EA003496B1 (enExample)
ES (1) ES2268888T3 (enExample)
IL (1) IL144135A0 (enExample)
LU (1) LU92425I2 (enExample)
MX (1) MXPA01006823A (enExample)
NO (2) NO310544B1 (enExample)
NZ (3) NZ545023A (enExample)
PT (1) PT1140212E (enExample)
TR (3) TR200201442T2 (enExample)
WO (1) WO2000040275A2 (enExample)
ZA (1) ZA200105431B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
AUPQ923100A0 (en) * 2000-08-07 2000-08-31 Peplin Research Pty Ltd Treatment of prostate cancer
AU2002364051A1 (en) * 2002-01-24 2003-09-02 Children's Medical Center Corporation Anti-cancer combination and use thereof
GB0213261D0 (en) * 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
DE602004009184T2 (de) 2003-04-30 2008-07-03 Ramot At Tel Aviv University Ltd. Verfahren und vorrichtung für die strahlentherapie
BRPI0507824A (pt) * 2004-02-20 2007-07-10 Algeta As hidroxiapatita, processo para a preparação de um particulado de hidroxiapatita marcada com radionuclìdeo, composição farmacêutica, uso de hidroxiapatita e de um radionuclìdeo emissor de alfa ou um radionuclìdeo emissor de beta, dispositivo, e, método de tratamento radioquìmico de um ser humano ou de um indivìduo animal não humano necessitando do mesmo
DE102004022200B4 (de) * 2004-05-05 2006-07-20 Actinium Pharmaceuticals, Inc. Radium-Target sowie Verfahren zu seiner Herstellung
US7914766B1 (en) * 2004-06-03 2011-03-29 Ut-Battelle Llc Inorganic resins for clinical use of 213Bi generators
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
PL1909855T3 (pl) * 2005-07-26 2018-09-28 Aplha Tau Medical Ltd. Promieniotwórcze źródło powierzchniowe i sposób jego wytwarzania
US8709380B1 (en) * 2006-02-07 2014-04-29 Sirius Medicine, Llc Targeting agents for enhancing radiation therapy
DE102006008023B4 (de) * 2006-02-21 2008-05-29 Actinium Pharmaceuticals, Inc. Verfahren zum Reinigen von 225Ac aus bestrahlten 226Ra-Targets
EP2796575B8 (en) * 2006-09-08 2020-04-01 Actinium Pharmaceuticals, Inc. Method for the purification of radium from different sources
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201007353D0 (en) * 2010-04-30 2010-06-16 Algeta Asa Method
GB201007354D0 (en) * 2010-04-30 2010-06-16 Algeta Asa Method
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
CA2895356A1 (en) 2012-12-19 2014-06-26 Bayer Pharma Aktiengesellschaft Combination comprising radium-223 for the treatment of cancer
GB201314718D0 (en) * 2013-08-16 2013-10-02 Algeta As Quantification method
EP3077003A1 (en) 2013-12-03 2016-10-12 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
WO2015082322A1 (en) 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft COMBINATION of PI3K-INHIBITORS
JP2016540771A (ja) 2013-12-17 2016-12-28 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ セロトニン−ノルアドレナリン再取り込み阻害薬（ｓｎｒｉ）およびシグマ受容体リガンドの組み合わせ
WO2016083739A1 (fr) 2014-11-26 2016-06-02 Rhodia Operations Composition de lanthane et d'actinium-227
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
CZ2016821A3 (cs) * 2016-12-22 2018-07-04 České vysoké učení technické v Praze Kombinace pro radionuklidovou terapii pro použití jako léčivo
UY37616A (es) 2017-02-24 2018-09-28 Bayer Ag Combinación de inhibidores de quinasa atr con sal de radio-223
CA3059534A1 (en) 2017-05-11 2018-11-15 Alpha Tau Medical Ltd. Polymer coatings for brachytherapy devices
CA3094785A1 (en) 2018-04-02 2019-10-10 Alpha Tau Medical Ltd. Controlled release of radionuclides
EP3563875A1 (en) * 2018-05-04 2019-11-06 Ceské vysoké ucení technické v Praze Radium for radionuclide therapy, in combination with calcium metabolism affecting treatment
LU100900B1 (de) * 2018-08-10 2020-02-17 Thomas Melchior Homann Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen
FR3086186B1 (fr) * 2018-09-26 2022-01-28 Orano Med Procede de production de plomb-212 a partir d'une solution aqueuse comprenant du thorium-228 et ses descendants
FR3088769B1 (fr) * 2018-11-15 2020-12-25 Orano Med Procede de preparation d'au moins un generateur a haute teneur en radium-228
WO2020180756A1 (en) * 2019-03-01 2020-09-10 Washington University Compositions and methods for radiotherapy using chelated radiotherapeutic agents and non-target tissue blockade
KR20220107058A (ko) 2019-12-05 2022-08-01 사이언콘스 에이에스 고순도 212Pb 생산
RU2752845C1 (ru) * 2020-05-13 2021-08-11 Акционерное Общество "Наука И Инновации" Способ получения высокочистого радия-223
MX2023007085A (es) * 2020-12-16 2023-06-26 Alpha Tau Medical Ltd Radioterapia de difusion de emisores alfa con tratamiento beta mejorado.
CN113066598B (zh) * 2021-03-25 2023-08-08 中国科学院近代物理研究所 一种从高能质子束辐照232Th靶引起的散裂反应中分离纯化223Ra的方法
US12076582B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for colorectal cancer
US12076583B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for melanoma
US12076581B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for glioblastoma
US11964168B2 (en) 2021-06-10 2024-04-23 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for prostate cancer
US12070620B2 (en) 2021-06-10 2024-08-27 Alpha Tau Medical Ltd. Activity levels for diffusing alpha-emitter radiation therapy
US12070621B2 (en) 2021-06-10 2024-08-27 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for pancreatic cancer
US12042668B2 (en) 2021-06-10 2024-07-23 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for squamous cell carcinoma
US12064643B2 (en) 2021-06-10 2024-08-20 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for breast cancer
WO2023159230A1 (en) 2022-02-21 2023-08-24 Bayer Healthcare Llc System, method and device for delivery of a therapeutic or diagnostic agent
EP4482574A1 (en) 2022-02-21 2025-01-01 Bayer HealthCare, LLC System, method and device for delivery of a therapeutic or diagnostic agent
CN115869658B (zh) * 2022-12-29 2025-01-28 中国核动力研究设计院 用于制备Ra-223的分离系统及其分离方法、应用和制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH668489A5 (de) * 1982-01-22 1988-12-30 Vnii Mineralnogo Syrya Radiometrisches verfahren zur bestimmung der konzentration natuerlicher radiumisotope und einrichtung zur durchfuehrung des verfahrens.
EP0438527A4 (en) * 1988-10-14 1992-07-01 Mallinckrodt, Inc. Radiolabelled particulate composition
US4970062A (en) * 1989-05-30 1990-11-13 The United States Of America As Represented By The United States Department Of Energy Colloid labelled with radionuclide and method
CA2123588A1 (en) * 1991-11-14 1993-05-27 Frederick C. Leung Method for diagnosing and treating cancer
CA2163107C (en) * 1993-05-17 2001-04-17 David Milton Goldenberg Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
US5809394A (en) * 1996-12-13 1998-09-15 Battelle Memorial Institute Methods of separating short half-life radionuclides from a mixture of radionuclides
US6117413A (en) * 1997-11-12 2000-09-12 Battelle Memorial Institute Radionuclide-binding compound, a radionuclide delivery system, a method of making a radium complexing compound, a method of extracting a radionuclide, and a method of delivering a radionuclide
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0213261D0 (en) * 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US20060228297A1 (en) * 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease

Also Published As

Publication number Publication date
TR200102707T2 (tr) 2002-03-21
BE2014C028I2 (enExample) 2019-03-05
NO2014010I2 (enExample) 2014-05-09
NO990001L (no) 2000-07-05
NZ513135A (en) 2004-09-24
EP1140212B1 (en) 2006-06-28
KR20010092772A (ko) 2001-10-26
CY2014020I1 (el) 2015-12-09
TR200201440T2 (tr) 2002-08-21
CN1767078A (zh) 2006-05-03
KR100671387B1 (ko) 2007-01-19
BR9916768A (pt) 2001-12-04
DE69932183T2 (de) 2007-05-16
WO2000040275A3 (en) 2001-06-21
ES2268888T3 (es) 2007-03-16
PT1140212E (pt) 2006-11-30
NO310544B1 (no) 2001-07-23
CN1767078B (zh) 2012-01-11
WO2000040275A2 (en) 2000-07-13
EP1140212A2 (en) 2001-10-10
TR200201442T2 (tr) 2002-08-21
US20030206857A1 (en) 2003-11-06
MXPA01006823A (es) 2003-07-14
NO2014010I1 (no) 2014-06-02
JP5433490B2 (ja) 2014-03-05
CY1105634T1 (el) 2010-12-22
DE69932183D1 (de) 2006-08-10
CY2014020I2 (el) 2015-12-09
EA200100642A1 (ru) 2002-02-28
NZ534618A (en) 2006-03-31
IL144135A0 (en) 2002-05-23
NZ545023A (en) 2007-08-31
US6635234B1 (en) 2003-10-21
JP4649044B2 (ja) 2011-03-09
ZA200105431B (en) 2002-07-02
HK1090750A1 (en) 2006-12-29
JP2010168397A (ja) 2010-08-05
DK1140212T3 (da) 2006-10-09
AU774991B2 (en) 2004-07-15
NO990001D0 (no) 1999-01-04
JP2002534399A (ja) 2002-10-15
CA2358498C (en) 2008-09-16
ATE331534T1 (de) 2006-07-15
EA003496B1 (ru) 2003-06-26
CN1335779A (zh) 2002-02-13
CA2358498A1 (en) 2000-07-13
LU92425I2 (fr) 2014-06-10
AU1700400A (en) 2000-07-24

Similar Documents

Publication Publication Date Title
CN1194764C (zh) 镭－223在制备用于治疗影响骨的疾病的药物中的用途
Henriksen et al. Significant antitumor effect from bone-seeking, α-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model
US7335154B2 (en) Radiotherapy
AU2001267734A1 (en) Radiotherapy
JP2019123731A (ja) 高純度治療用骨剤
JPH0662440B2 (ja) 石灰性腫瘍の治療のためのアミノカルボン酸錯体
HK1090750B (en) Methods of preparing radium-223, and pharmaceutically acceptable agents and reagent set
US11813339B2 (en) Method of use for therapeutic bone agents
NO317110B1 (no) Nytt radiofarmasoytisk preparat

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20151130

Address after: Oslo, Norway

Patentee after: BAYER AG

Address before: Oslo, Norway

Patentee before: Anticancer Therapeutic Inventions A/S

CX01 Expiry of patent term

Granted publication date: 20050330

CX01 Expiry of patent term